Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Change in Account Payables: 2009-2024

Historic Change in Account Payables for Madrigal Pharmaceuticals (MDGL) over the last 16 years, with Dec 2024 value amounting to $15.6 million.

  • Madrigal Pharmaceuticals' Change in Account Payables fell 83.88% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 million, marking a year-over-year decrease of 106.90%. This contributed to the annual value of $15.6 million for FY2024, which is 269.55% up from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its Change in Account Payables stood at $15.6 million for FY2024, which was up 269.55% from $4.2 million recorded in FY2023.
  • In the past 5 years, Madrigal Pharmaceuticals' Change in Account Payables ranged from a high of $20.4 million in FY2021 and a low of -$161,000 during FY2020.
  • Its 3-year average for Change in Account Payables is $7.4 million, with a median of $4.2 million in 2023.
  • In the last 5 years, Madrigal Pharmaceuticals' Change in Account Payables surged by 12,747.83% in 2021 and then plummeted by 87.96% in 2022.
  • Yearly analysis of 5 years shows Madrigal Pharmaceuticals' Change in Account Payables stood at -$161,000 in 2020, then skyrocketed by 12,747.83% to $20.4 million in 2021, then tumbled by 87.96% to $2.5 million in 2022, then skyrocketed by 71.77% to $4.2 million in 2023, then skyrocketed by 269.55% to $15.6 million in 2024.